VIDAS? LYME IGG 30320

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2016-03-15 for VIDAS? LYME IGG 30320 manufactured by Biomerieux Sa.

Event Text Entries

[40352391] A customer in (b)(6) reported a false negative result while using product; vidas lyme igg test kit. There were no reports of patient harm.
Patient Sequence No: 1, Text Type: D, B5


[46134775] A customer in (b)(6) reported a false negative result while using product; vidas lyme igg test kit. An internal biom? Rieux investigation was performed with results as follows: no additional complaints for vidas lyme igg test kit lot 1004350980/160914-0 since january 2015. Analysis of batch history records indicates there was no anomaly detected during the control process. Tested one (1) negative sample and three (3) positive samples on the retained vidas lyme igg test kit lot 1004350980. Results- results obtained for the four (4) samples, were within specifications. Analysis of the control card for these four (4) samples show that vidas lyme igg lot 1004350980 is in trend with other lots. Western blot test igg result- there were only three (3) positive bands with two (2) representing early markers (p41 and ospc). On the western blot test igm, there were five (5) positive bands with four (4) representing early markers (ospc). Vidas- negative control result (c2 ) was 0. 00 vt while the sample result was 0. 10 vt with a low detection, which may represent an early infection with igg present but at a rate too low to be detected positive; however, at a sufficiently high rate to be detected by western blot, which is a more sensitive method. Per the vidas lyme igg package insert, antibody detection methods do not provide definitive results for establishing or ruling out a diagnosis of lyme borreliosis. A negative result in the vidas lyme igm and vidas lyme igg assays does not rule out the possibility of b. Burgdorferi infection in a patient. Patients in early stages of infection or who have undergone antibiotic therapy, may not produce measurable igm and igg. Patients with clinical history and/or symptoms suggestive of lyme disease, but with negative test results, should be reported as "no detectable antibodies to b. Burgdorferi. " a second specimen should be collected in 4-6 weeks. It is estimated that in 50% of subjects, in the primary stage of disease, antibody levels in blood remain below the detectable threshold. Conclusion- vidas lyme igg test kit is performing within acceptable limitations as noted in the package insert.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number3002769706-2016-00055
MDR Report Key5501162
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2016-03-15
Date of Report2016-03-09
Date Mfgr Received2016-03-09
Date Added to Maude2016-03-15
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMR. RYAN LEMELLE
Manufacturer Street595 ANGLUM ROAD
Manufacturer CityHAZELWOOD MO 63042
Manufacturer CountryUS
Manufacturer Postal63042
Manufacturer Phone3147318582
Manufacturer G1BIOMERIEUX SA
Manufacturer Street595 ANGLUM ROAD
Manufacturer CityST. LOUIS MO 63042
Manufacturer CountryUS
Manufacturer Postal Code63042
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameVIDAS? LYME IGG
Generic NameVIDAS? LYME IGG
Product CodeLSR
Date Received2016-03-15
Catalog Number30320
Lot Number1004350980
Device Expiration Date2016-09-14
OperatorHEALTH PROFESSIONAL
Device Availability*
Device AgeDA
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerBIOMERIEUX SA
Manufacturer AddressCHEMIN DE L ORME MARCY L ETOILE, RHONE 69280 FR 69280


Patients

Patient NumberTreatmentOutcomeDate
10 2016-03-15

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.